Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII

Haemophilia

Volumn 18, Issue 1, 2012, Pages

  Tokgoz, H ^a   Caliskan, U ^a   Lavigne Lissalde, G ^b   Giansily Blaizot, M ^c  

^a SELCUK UNIVERSITY   (Turkey)

^b UMR 3145 SysDiag CNRS/Bio Rad   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ANTIBODY TITER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; CASE REPORT; FOLLOW UP; HUMAN; INFANT; LETTER; MALE; NONSENSE MUTATION; PRIORITY JOURNAL; RECURRENT DISEASE;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VII DEFICIENCY; FACTOR VIIA; HUMANS; INFANT; INTRACRANIAL HEMORRHAGES; MALE; RECOMBINANT PROTEINS; SEIZURES; TREATMENT OUTCOME;

EID: 84355162163     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02666.x     Document Type: Letter

References (10)

1. Mariani G, Herrmann FH, Dolce A et al. International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
2. Lavigne-Lissalde G, Tarrade C, Lapalud P et al. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 1090-6.
3. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
4. Karimi M. Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath. Semin Hematol 2008; 2(Suppl. 1): S74.
5. Mathijssen NC, Masereeuw R, Verbeek K et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-9.
6. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): 119-23.
7. Ingerslev J, Christiansen K, Sørensen B. International Registry on Factor VII Deficiency (IRF7) Steering Committee. Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response. J Thromb Haemost 2005; 3: 799-800.
8. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 5: 1403-8.
9. Giansily-Blaizot M, Schved JF. Potential predictors of bleeding risk in inherited factor VII deficiency. Clinical, biological and molecular criteria. Thromb Haemost 2005; 94: 901-6.
10. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet 2004; 36: 801-8.